Luzu (Luliconazole) Patent Expiration, LOE Window & CMS Spending

Luzu (Luliconazole) by Bausch Health: FDA Orange Book core substance LOE 2033-09-06 (last listed 2034-04-28), 0 AB generics, $34K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBausch Health
FDA Application & PathwayN204153 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2033-09-06
Last Listed Patent or Exclusivity Date2034-04-28
Orange Book Patents (*PED Extensions)4 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$34K
2024 Medicare Part D Spend$6K
2024 Medicaid Spend$28K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bausch Health / Bausch + Lomb across sibling Meru public-data platforms.